FSUE Moscow Endocrine Plant (Endopharm) has registered Anidulafungin, a new domestic antifungal drug for the treatment of severe forms of candidiasis, in the form of a 100 mg lyophilizate for the preparation of concentrate and infusion solution. The company’s press service stated that it is planned to start industrial production of the drug at the new manufacturing site of the Lefortovsky branch in the second half of 2026.
Endopharm added that Anidulafungin will be the first in the Russian company’s line of antifungal drugs developed for the treatment of severe forms of candidiasis in adults and children.
The drug is included in clinical treatment protocols for eliminating the effects of the localization of Candida in internal organs (brain, eyes, heart, bones, lungs) or in the blood (candidaemia). The drug is also used in the treatment of esophageal candidiasis in adult patients.
According to the state register, 10 drugs based on the active substance anidulafungin have been registered in Russia. The original drug under the trade name Eraxis is produced by the American pharmaceutical company Pfizer.
Anidulafungin eliminates dangerous fungi by disrupting their cell wall, particularly targeting Candida species. It blocks a special enzyme that fungi need for growth and reproduction. The drug can also inhibit the growth of another fungus, Aspergillus fumigatus. Anidulafungin is administered intravenously.
